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Abstract
Background: Hydroxychavicol, isolated from the chloroform extraction of the aqueous leaf extract of Piper betle L.,
(Piperaceae) was investigated for its antifungal activity against 124 strains of selected fungi. The leaves of this plant
have been long in use tropical countries for the preparation of traditional herbal remedies.
Methods: The minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) of
hydroxychavicol were determined by using broth microdilution method following CLSI guidelines. Time kill curve
studies, post-antifungal effects and mutation prevention concentrations were determined against Candida species
and Aspergillus species “respectively”. Hydroxychavicol was also tested for its potential to inhibit and reduce the
formation of Candida albicans biofilms. The membrane permeability was measured by the uptake of propidium
iodide.
Results: Hydroxychavicol exhibited inhibitory effect on fungal species of clinical significance, with the MICs ranging
from 15.62 to 500 μg/ml for yeasts, 125 to 500 μg/ml for Aspergillus species, and 7.81 to 62.5 μg/ml for
dermatophytes where as the MFCs were found to be similar or two fold greater than the MICs. There was
concentration-dependent killing of Candida albicans and Candida glabrata up to 8 × MIC. Hydroxychavicol also
exhibited an extended post antifungal effect of 6.25 to 8.70 h at 4 × MIC for Candida species and suppressed the
emergence of mutants of the fungal species tested at 2 × to 8 × MIC concentration. Furthermore, it also inhibited
the growth of biofilm generated by C. albicans and reduced the preformed biofilms. There was increased uptake of
propidium iodide by C. albicans cells when exposed to hydroxychavicol thus indicating that the membrane
disruption could be the probable mode of action of hydroxychavicol.
Conclusions: The antifungal activity exhibited by this compound warrants its use as an antifungal agent
particularly for treating topical infections, as well as gargle mouthwash against oral Candida infections.
Background
Mycosis constitutes a common health problem, espe-
cially in tropical and subtropical developing countries;
dermatophytes, Malassezia species and Candida species
being the most frequent pathogens in humans and ani-
mals [1]. In recent years, there has been an increasing
search for new antifungal agents. However, since many
of the available antifungal drugs have undesirable side
effects or are very toxic (amphotericin B), produce
recurrence, show drug-drug interactions (azoles) or lead
to the development of resistance (fluconazole, 5-
flucytosine), some shows ineffectiveness [2,3] and have
become therefore less successful in therapeutic strate-
gies. Therefore it is necessary to search for more effec-
tive and less toxic novel antifungal agents that would
overcome these disadvantages. Interestingly, plants are
widely employed in folk medicine, mainly in commu-
nities with inadequate conditions of public health and
sanitation. Several medicinal plants have been exten-
sively studied in order to find more effective and less
toxic compounds [4].
Piper betle L., (Piperaceae) has been extensively used
in traditional herbal remedies in India, China, Taiwan,
Thailand and many other countries. It is reported for
various pharmacological activities such as antimicrobial,
antioxidant, antimutagenic, anticarcinogenic,
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any medium, provided the original work is properly cited.antiinflammatory [5] etc. Ita l s oa c t sa sas t i m u l a n t ,a
breath freshener, a carminative, a sialagogue, a cardiac
tonic, a pain killer in joint pain, an aphrodisiac, an
astringent, an antiseptic [5-7], a digestive and pancreatic
lipase stimulant [8], wound healing [9].
Hydroxychavicol is the major phenolic component,
isolated from the aqueous extract of P. betle L., leaf has
been reported to possess antinitrosation, antimutagenic,
anticarcinogenic activities [10]. It also has a tendency to
act as an antioxidant, and a chemopreventive agent [10].
Other useful properties include antiinflammatory, anti-
platelet and antithrombotic without impairing haemo-
static functions [11]. There have been reports on the
antibacterial activities of hydroxychavicol [12,13], but so
far the report on its antifungal activity is lacking.
The present study was sought to investigate the effects
of hydroxychavicol on fungal pathogens. In addition its
effect on membrane permeability of C. albicans was also
examined.
Methods
Antifungal agents
Hydroxychavicol (Fig. 1) was isolated in the pure form
from the chloroform extraction of the aqueous leaf
extract of P. betle L., (Piperaceae) as described pre-
viously [12]. Amphotericin B was purchased from Sigma
Chemical Co. (St. Louis, MO), and terbinafine was
obtained as kind gift from Lupin Laboratories, Pune,
India.
Fluorochrome dye
Propidium iodide (Sigma), a small cationic, nucleic acid-
binding fluorochrome largely excluded by intact cell
membranes was used to stain the yeast cells [14].
Sodium deoxycholate (Sigma), an anionic detergent, was
used to facilitate diffusion of propidium iodide into the
yeast cell membranes which were damaged by the anti-
fungal agent [15].
Fungal strains and growth conditions
A total of 124 fungal strains were tested for their sus-
ceptibility to hydroxychavicol. These strains comprised
of Candida albicans (ATCC 90028, ATCC 10231 and
23 clinical isolates), Candida glabrata (ATCC 90030
and 7 clinical isolates), Candida krusei (ATCC 6258 and
3 clinical isolates), Candida parapsilosis (ATCC 22019
and 5 clinical isolates), Candida tropicalis (ATCC 750
and 11 clinical isolates), Cryptococcus neoformans
(ATCC 204092 and 2 clinical isolates), Aspergillus flavus
(MTCC 1973, MTCC 2799 and 10 clinical isolates),
Aspergillus fumigatus (MTCC 1811 and 17 clinical iso-
lates), Aspergillus niger (ATCC 16404 and 6 clinical iso-
lates), Aspergillus parasiticus (MTCC 2796),
Epidermophyton floccosum (MTCC 613 and 1 clinical
isolate), Microsporum canis (MTCC 2820 and 3 clinical
isolates), Microsporum gypsium (MTCC 2819 and 2 clin-
ical isolates), Trichophyton mentagrophytes (ATCC 9533
and 7 clinical isolates), and Trichophyton rubrum
(MTCC 296 and 9 clinical isolates). Reference strains
were procured from the American Type Culture Collec-
tion (ATCC, Manassas, VA, USA), and Microbial Type
Culture Collection (MTCC, Chandigarh, India). The
clinical isolates were obtained from the Department of
Microbiology, Acharya Shri Chander College of Medical
Sciences, Sidhra, Jammu, India.
“Inoculum” preparation
Suspensions of the yeasts and Aspergillus species were
prepared in sterile normal saline (0.85%) containing
0.05% polysorbate 20 (NST) from 24 h (48 h for C. neo-
formans) and 7-day-old cultures “respectively” grown on
potato dextrose agar (Difco Laboratories, Detroit, Mich)
at 35°C [16,17]. A stock inoculums suspension of each
dermatophytes was prepared from fresh, mature (7-day-
old) cultures grown on potato dextrose agar with 2% in-
house rice flour slants at 28°C. The densities of these
suspensions were adjusted with a spectrophotometer
(Multiskan spectrum, Thermo electron, Vantaa, Finland)
at a wavelength of 530 nm to a transmittance of 65 to
70% to yield an initial inoculum of 1 × 10
6 to 5 × 10
6
cfu/ml [18]. All adjusted suspensions were quantified by
plating on Sabouraud dextrose agar (SDA; Difco Labora-
tories) plates.
MIC and MFC determination of hydroxychavicol
The MIC was performed by broth microdilution methods
as per the guidelines of Clinical and Laboratory Standard
Institute (formerly, the National Committee for Clinical
Laboratory Standards) [16,17], with RPMI 1640 medium
Figure 1 Structure of hydroxychavicol.
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Page 2 of 9Figure 2 Time-kill curve plots for Candida species following exposure to hydroxychavicol (HC). C. albicans ATCC 90028 (A), C. glabrata
ATCC 90030 (B). Each time point represents the mean log10 ± standard deviations of two different experiments performed in duplicate. P
values < 0.001 (Student’s t-test).
Ali et al. Annals of Clinical Microbiology and Antimicrobials 2010, 9:7
http://www.ann-clinmicrob.com/content/9/1/7
Page 3 of 9containing L-glutamine, without sodium bicarbonate and
buffered to pH 7.0 with 0.165 M morpholinepropanesul-
fonic acid (RPMI) (both from Sigma). Stock solution of
hydroxychavicol was prepared in 100% dimethyl sulfox-
ide (DMSO; Sigma) and twofold serial dilutions were pre-
pared in media in amounts of 100 μl per well in 96-well
U-bottom microtiter plates (Tarson, Mumbai, India). The
above-mentioned fungal suspensions were further diluted
in media, and a 100 μl volume of this diluted inoculum
was added to each well of the plate, resulting in a final
inoculum of 0.5 × 10
4 to 2.5 × 10
4 cfu/ml [19] for yeasts
and 0.4 × 10
4 to 5 × 10
4 cfu/ml for dermatophytes and
Aspergillus species. The final concentration of hydroxy-
chavicol ranged from 3.90 to 2000 μg/ml. The medium
without the agents was used as a growth control and the
blank control used contained only the medium. Ampho-
tericin B and terbinafine served as the standard drug con-
trols. The microtiter plates were incubated at 28°C for 7
days for dermatophytes [18], and at 35°C for 48 h for
Candida species (72 h for C. neoformans) and Aspergillus
species [16,17]. The plates were read visually, and the
MIC was defined as the lowest concentration of the anti-
fungal agents that prevented visible growth with respect
to the growth control.
The MFC was determined by plating a 100 μlv o l u m e
on SDA from the wells showing no visible growth. The
plates were incubated as described above in MIC. The
minimum concentration of hydroxychavicol that showed
≥ 99.9% reduction of the original inoculums was
recorded as the MFC [19].
Time kill curve studies
Time-kill curve studies were performed as described by
Ernst et al [20], using RPMI. C. albicans ATCC 90028
and C. glabrata ATCC 90030 were used as the test
strains in this study. One milliliter of the adjusted
inoculum suspension (≈ 5×1 0
6 cfu/ml) was added to
nine ml of RPMI with or without hydroxychavicol,
providing the starting inoculum of ≈ 5×1 0
5 cfu/ml.
The range of hydroxychavicol concentrations tested
was one to eight times the MICs for test strains i.e.
250 to 2000 μg/ml for C. albicans and 31.5 to 250 μg/
ml for C. glabrata. The culture flasks were incubated
with agitation at 35°C. At predetermined time points
(0, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 h following the
addition of hydroxychavicol), a 100 μl aliquot was
removed from each culture flask and serially diluted in
sterile normal saline containing 0.1% polysorbate 80
(Sigma) for the inactivation of hydroxychavicol. A 20
μl aliquot was plated onto a Sabouraud dextrose agar
with lecithin and polysorbate 80 (BBL, Becton Dickin-
son and Company, Cockeysville, MD) plate for colony
count determination. When the colony counts were
expected to be less than 1000 cfu/ml, samples of 20 μl
or 100 μl were taken directly from the test solution
and plated or subcultured without dilution. Plates were
then incubated at 35°C for 24 to 48 h. The lower limit
of accurate and reproducible quantification was 50 cfu/
ml for each of the strains.
Postantifungal effect (PAFE)
The PAFE of hydroxychavicol was performed in RPMI
by the method described by Craig and Gudmundsson
[21]. C. albicans ATCC 90028, C. tropicalis ATCC 750,
C. glabrata ATCC 90030 and C. parapsilosis ATCC
22019 were used as the test strains in this study. One
milliliter of the adjusted inoculum suspension (≈ 5×
10
7 cfu/ml) was added to nine ml of RPMI with or with-
out hydroxychavicol, providing the starting inoculum of
≈ 5×1 0
6cfu/ml. The hydroxychavicol concentrations
ranged from one to four times the MIC. After exposures
to the hydroxychavicol for 2 h, samples were diluted to
1: 1,000 in prewarmed medium to effectively remove the
hydroxychavicol. The diluted cultures were then incu-
bated with agitation (200 rpm) at 35°C and sampling
was done after 0, 2, 4, 6, 8, 10, 12, 16 and 24 h for col-
ony counts. The colony counts were determined as
described above in time-kill curve studies. The PAFE
was calculated by the following equation: PAFE = T-C,
where T represents the time required for the count in
the test culture to increase 1 log10 cfu/ml above the
count observed immediately after drug (hydroxychavi-
col) removal and C represents the time required for the
count of the untreated control flask to increase by 1
log10 cfu/ml.
Selection of resistant mutants in vitro
The first step mutant frequency of reference strains of
C. albicans ATCC 90028, C. tropicalis ATCC 750, C.
glabrata ATCC 90030, C. parapsilosis ATCC 22019, A.
flavus MTCC 2799 and A. fumigatus MTCC 1811 were
selected, using previously described method [22]. A fun-
gal suspension containing 10
9 cfu (100 μl) was plated on
SDA containing hydroxychavicol at concentrations equal
to two, four and eight times the MIC. Mutation fre-
quency was calculated by counting the total number of
colonies appearing after 48 h of incubation at 35°C on
the hydroxychavicol containing plate and by dividing the
number by the total number of cfu plated.
Minimum biofilm inhibitory concentrations (MBICs)
The effect of hydroxychavicol on C. albicans ATCC
90028 biofilm formation was examined by the micro-
broth dilution method, similar to MIC assays for plank-
tonic cells [16] as described above. The fungal
suspension was prepared from the overnight culture
grown in yeast nitrogen base (Difco Laboratories) med-
ium supplemented with 100 mM glucose [23], and the
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phase, washed twice with sterile phosphate-buffered sal-
ine (PBS; pH 7.2; Ca
2+ and Mg
2+ free [Hi Media]) and
the turbidity of the suspension was adjusted to 4 McFar-
land standard (≈ 5×1 0
7 cfu/ml). The suspension was
diluted in RPMI to obtain ≈ 5×1 0
6 cfu/ml as the final
inoculums. Twofold serial dilutions of hydroxychavicol
were prepared in RPMI in the wells of a 96-well flat-
bottom polystyrene microtiter plate (NUNC, Roskilde,
Denmark) containing the same media in a volume of
100 μl per well. A 100 μl of above-mentioned suspen-
sion was added to each well; the final concentrations of
hydroxychavicol ranged from 1.95 to 2000 μg/ml.
Amphotericin B (at a final concentration range from
0.0156 to 16 μg/ml) was used as control drug. Following
incubation at 35°C for 48 h, absorbance at 490 nm was
recorded to assess culture growth. The culture superna-
tants from each well were then decanted, and planktonic
cells were removed by washing the wells with sterile
PBS. Biofilm formation was quantified by tetrazolium
salt (XTT) reduction assay (see below).
Minimum biofilm reduction concentrations (MBRCs)
The effect of hydroxychavicol was also examined on
preformed C. albicans ATCC 90028 biofilm by the
method as described previously [24]. Biofilms were pre-
pared by inoculating the wells of a polystyrene microti-
ter plate in a manner similar to that described above.
After incubation at 35°C for 48 h, the culture superna-
tant from each well was decanted, and the planktonic
cells were removed by washing the wells with PBS. Two
fold serial dilutions of hydroxychavicol were prepared in
RPMI, and 200 μl of each dilution was added to the bio-
film in the wells. The plate was further incubated at 35°
C for 48 h. The final concentrations of hydroxychavicol
ranged from 1.95 to 2000 μg/ml. Amphotericin B (at a
final concentration range from 0.0156 to 16 μg/ml) was
used as control drug. After the completion of incuba-
tion, the plates were decanted and washed three times
with 200 μl of sterile PBS to remove loosely adherent
cells. Biofilm reduction was quantified by XTT-reduc-
tion assay described below.
XTT-reduction assay
XTT (tetrazolium salt 2, 3-bis (2-methoxy-4-nitro-5-
sulfo-phenyl)-2H-tetrazolium-5-carboxanilide) reduction
assay was performed by the method as described by Jin
et al., [23]. The XTT (Sigma) solution was prepared in
PBS (1 mg/ml), filter-sterilized through a 0.22-μm-pore-
size filter (Millipore, Bangalore, India) and stored at -80°
C until required. Menadione (Sigma) solution (0.4 mM
prepared in acetone) was filtered and mixed with XTT
solution at a ratio of 1 to 5 by volume before the assay.
200 μl of PBS and 12 μl of the XTT-Menadione solution
were added to each of the washed wells and the plate
was incubated in the dark for 2 h at 35°C. Following
incubation, 100 μl of the solution was transferred to a
fresh microtiter plate and, the color change in the solu-
tion was measured spectrophometrically using a microti-
tre plate reader (Multiskan spectrum, Thermo electron,
Vantaa, Finland) at 490 nm.
Table 1 MICs and MFCs of hydroxychavicol for 124
strains of selected fungi determined by the broth
microdilution method
Species No of strains
tested
Antifungal activity in
μg/ml
MIC
range
MFC
range
C. albicans ATCC 90028,
10231
2 250 250
C. albicans (CI) 23 125 - 500 250 - 500
C. glabrata ATCC 90030 1 31.25 31.25
C. glabrata (CI) 7 15.62 -
31.25
15.62 -
62.5
C. krusei ATCC 6258 1 15.62 15.62
C. krusei(CI) 3 15.62 -
31.25
15.62 -
31.25
C. parapsilosis ATCC 22019 1 31.25 31.25
C. parapsilosis (CI) 5 31.25 -
62.5
31.25 -
62.5
C. tropicalis ATCC 750 1 250 250
C. tropicalis (CI) 11 125 - 500 250 - 500
C. neoformans ATCC
204092
1 62.5 62.5
C. neoformans (CI) 2 62.5 62.5
A. flavus MTCC 1973, 2799 2 250 250
A. flavus (CI) 11 125 - 500 125 - 500
A. fumigatus MTCC 1811 1 250 250
A. fumigatus (CI) 17 125 - 500 250 - 500
A. niger ATCC 16404 1 125 125
A. niger (CI) 6 125 - 250 125 - 250
A. parasiticus MTCC 2796 1 250 250
E. floccosum MTCC 613 1 15.62 15.62
E. floccosum(CI) 1 15.62 31.25
M. canis MTCC 2820 1 15.62 31.25
M. canis (CI) 3 7.81- 15.62 15.62 -
31.25
M. gypsium MTCC 2819 1 15.62 31.25
M. gypsium(CI) 2 15.62 -
31.25
31.25 -
62.5
T. mentagrophytes ATCC
9533
1 15.62 15.62
T. mentagrophytes (CI) 7 15.62 -
31.25
15.62 -
62.5
T. rubrum MTCC 296 1 31.25 31.25
T. rubrum (CI) 9 15.62 -
62.5
31.25 -
62.5
MIC and MFC of yeast was determined by using higher inoculums [19]. CI,
clinical isolate.
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The disruptive effect of hydroxychavicol on Candida
albicans ATCC 90028 cell membranes was assessed by
using hydroxychavicol-mediated propidium iodide
uptake. One-milliliter volumes of ≈ 5×1 0
7 cfu/ml cell
suspensions of C. albicans in sterile MilliQ water were
incubated with two to eight times the MIC (500 to 2000
μg/ml) of hydroxychavicol at 35°C for 60 min under agi-
tation in the dark chamber. Fifteen minutes prior to the
completion of incubation, 10 μl each of propidium
iodide and sodium deoxycholate solution were added at
a final concentration of 25 μg/ml and 2.5 mg/ml
“respectively” [14,15]. Amphotericin B at eight times the
MIC (4.0 μg/ml) was used as the positive control and,
the cells without hydroxychavicol served as the negative
(growth) control, treated in similar fashion. After incu-
bation, 50 μl aliquot was transferred into fluorescence-
activated cell sorting (FACS) tube (Becton Dickinson
Biosciences, CA) containing 950 μl of sterile MilliQ
water. Each tube was analyzed using a FACScan flow
cytometer (BD-LSR; Becton Dickinson) with Cell Quest
Pro software for data acquisition and analysis.
Results
Antifungal susceptibility results
The MICs and MFCs of hydroxychavicol were evaluated
in vitroagainst 58 strains of yeasts, 39 strains of Aspergil-
lus species and 27 strains of dermatophytes and all
values are listed in Table 1. Hydroxychavicol exhibited
the MICs range between 15.62 to 500 μg/ml for yeasts,
125 to 500 μg/ml for Aspergillus species and 7.81 to
62.5 μg/ml for dermatophytes, where as the MFCs were
found to be similar or two fold greater than the MICs.
Among all the fungal species tested, dermatophytes
were found to be the most susceptible species to
hydroxychavicol.
Time kill curve studies
The killing activities of hydroxychavicol for C. albicans
ATCC 90028 and C. glabrata ATCC 90030 are shown
Table 2 PAFE values of hydroxychavicol for Candida species after 2 h of exposure
Species PAFEs (h) (mean ± SD) at the following multiple of the MIC:
1 × MIC 2 × MIC 4 × MIC
C. albicans ATCC 90028 5.53 ± 0.3 6.34 ± 0.2 8.64 ± 0.3
C. tropicalis ATCC 750 4.4 ± 0.6 6.4 ± 0.4 8.70 ± 0.2
C. glabrata ATCC 90030 3.08 ± 0.4 3.76 ± 0.6 8.04 ± 0.1
C. parapsilosis ATCC 22019 2.0 ± 0.1 4.0 ± 0.2 6.25 ± 0.3
Table 3 Frequency of mutation with hydroxychavicol
Tested strains Mutation frequency with
hydroxychavicol at:
2 × MIC 4 × MIC 8 × MIC
C. albicans ATCC 90028 2.5 × 10
9 <10
9 <10
9
C. tropicalis ATCC 750 2 × 10
9 <10
9 <10
9
C. glabrata ATCC 90030 1.5 × 10
9 1.5 × 10
9 <10
9
C. parapsilosis ATCC 22019 2 × 10
9 2×1 0
9 <10
9
A. fumigatus MTCC 1811 <10
9 <10
9 <10
9
A. flavus MTCC 1973 <10
9 <10
9 <10
9
MIC of hydroxychavicol is 31.25 μg/ml for C. glabrata and C. parapsilosis while
as 250 μg/ml for other species tested.
Figure 3 Inhibitory effect of hydroxychavicol (HC) on the
biofilm formation (A) and reduction (preformed) (B) of C.
albicans ATCC 90028 biofilms. After incubation, the biofilm
viability was quantified by XTT reduction assay at absorbance of 490
nm. The results are expressed as average optical density readings
for XTT assays compared to growth control. Values represent the
mean and standard deviations of three different experiments
performed in quadruplicate. P values < 0.05 (Student’s t-test).
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against both Candida species and the reduction in the
number of cfu per milliliter was greater than 3 log units
(99.9%). The fungicidal endpoint for C. albicans was
achieved after 10 and 1 h at 4 × MIC (4 × 250 μg/ml)
a n d8×M I C( 8×2 5 0μg/ml) of hydroxychavicol (Fig.
2A). In C. glabrata, killing was observed at a lower con-
centration of hydroxychavicol due to its lower MIC.
There was concentration dependent killing observed in
case of C. glabrata,w i t ht w o ,f o u ra n de i g h tt i m e st h e
MIC exhibited fungicidal activity in 10, 8 and 4 h
“respectively”.
PAFE studies
Hydroxychavicol produced significant PAFE against all
the Candida species tested (Table 2). Increase in the
concentration of hydroxychavicol resulted in extended
PAFE for all the Candida spp. tested. This increase in
PAFE was more prominent for C. albicans and C. tropi-
calis, where a PAFE of >8 h was exhibited in these
organisms at four times the MIC concentration of
hydroxychavicol.
Frequency of emergence of hydroxychavicol resistant
mutants
The frequencies of mutant selection of C. albicans, C.
tropicalis, C. glabrata, C. parapsilosis, A. fumigatus, and
A. flavus, are summarized in Table 3. Hydroxychavicol
completely suppressed the emergence of mutants at two
times its MIC for A. fumigatus and A. flavus, four times
the MIC for C. albicans and C. tropicalis,a n de i g h t
times the MIC for C. glabrata and C. parapsilosis
“respectively”. This concentration of hydroxychavicol at
which no mutant was selected can be defined as the
mutation prevention concentration.
Biofilm susceptibility assay
Hydroxychavicol exhibited an inhibitory effect on the
biofilm formation and reduction of preformed biofilm of
C. albicans ATCC 90028. The 50% and 80% biofilm
inhibition as well as biofilm reduction are represented in
Fig. 3. The MBIC50 and MBIC80 values of hydroxychavi-
col were 125 μg/ml and 250 μg/ml, where as the
MBRC50 and MBRC80values were 500 μg/ml and 1000
μg/ml. Reductions of preformed biofilms values were
four fold greater than the concentration required to
inhibit biofilm formation.
Effect of hydroxychavicol on membrane permeability
Exposing the cell suspension of C. albicans ATCC
90028 to two to eight times (500 to 2000 μg/ml) the
MIC of hydroxychavicol for 60 min increased the cell
permeability to the fluorescent nucleic acid stain, propi-
dium iodide due to the disruption of membrane integ-
rity. This resulted in the increase in fluorescence in
comparison to untreated control (Fig. 4). This increase
in fluorescence was proportional to the increase in the
hydroxychavicol concentrations.
Discussion
In this study, we evaluated the antifungal activities of
hydroxychavicol against various fungal species. Hydroxy-
chavicol demonstrated fungicidal effects against all the
fungal species tested including Candida spp., Aspergillus
spp. and dermatophytes. The fungicidal effect was most
pronounced in dermatophytes including T. rubrum
(MICs and MFCs were 15.62 - 62.5 μg/ml) which is the
etiological agent of 80 to 93% of all clinical infections
produced by dermatophytes [3]. Hydroxychavicol also
exhibited concentration dependent killing and extended
PAFE of > 8 h. In the concentration range of 250-1000
μg/ml it completely suppressed the emergence of
mutants of various Candida and Aspergillus species
tested.
C. albicans is most commonly associated with biofilm
formation, and the increase in Candida infections in the
last decades has almost paralleled the increase and wide-
spread use of a broad range of medical implant devices
(such as stents, prostheses, implants, endotracheal tubes,
pacemakers, and catheters), mainly in populations with
impaired host defenses. Biofilm formation on medical
devices can negatively impact the host by causing the
failure of the device and by serving as a reservoir or
source for future continuing infections [25]. Hydroxy-
chavicol was effective in inhibiting the C. albicans
Figure 4 Uptake of propidium iodide in cell suspension of C.
albicans ATCC 90028. Cells (≈ 5×1 0
7cfu/ml) were exposed to
two to eight times (500 to 2000 μg/ml) the MIC of hydroxychavicol
(HC) for 60 min. Amphotericin B at eight times the MIC (4.0 μg/ml)
was used as the positive control and, the cells without
hydroxychavicol served as the growth control. Data represent the
mean and standard deviations of two different experiments
performed in triplicate. P values < 0.05 (Student’s t-test).
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observed at the MIC concentration (250 μg/ml). How-
ever the reduction of the preformed biofilm was seen at
four fold greater concentrations.
There have been reports on the antifungal activities of
P. betle. Pongpech and Prasertsilpe [26] found that P.
betle gel inhibited growth of dermatophytes that cause
ringworm and growth of Candida species more effec-
tively than tolnaftate and with a similar inhibitory effect
to that of clotrimazole. Recently, Trakranrungsie et al
[27] also reported the antidermatophytic activity of P.
betle extract against M. canis, M. gypseum and T. men-
tagrophyte by broth dilution method and showed that P.
betle exhibited more effective antifungal properties with
average IC50 and IC90 values ranging from 110.44 to
119.00 μg/ml and 230.40 to 492.30 μg/ml “respectively”.
Hydroxychavicol is one of the major constituents of P.
betle. It has been extensively reported for its antibacter-
ial activity [12,13]. However its antifungal activity has
not been reported so far. Here in this study we have for
the first time reported the antifungal potential of
hydroxychavicol.
Propidium iodide is a fluorescent nucleic acid stain that
is unable to penetrate the cell membrane structures of
healthy cells. However, cells with damaged or permeabi-
lised cell membranes do not exclude propidium iodide.
Therefore, propidium iodide staining of cells indicates
cytoplasmic membrane (bacteria) and plasma membrane
(yeast) damage [28]. Sodium deoxycholate was used in
this study as it is reported to enhance the diffusion of
propidium iodide across the cell wall to pass through the
damaged yeast cell membranes [29,15]. Interestingly, the
growth controls did not show dye uptake in the presence
of deoxycholate as the deoxycholate is nontoxic to C.
albicans [29]. The increased uptake of propidium iodide
in the hydroxychavicol treated cells of C. albicans in our
study, further confirmed the earlier findings that hydro-
xychavicol alters the cell membrane structure, resulting
in the disruption of the permeability barrier of microbial
membrane structures [30].
The clinical applications of hydroxychavicol were chal-
lenging to interpret in this study due to a lack of phar-
macokinetic and safety studies. However its comparable
cytotoxicity profile with that of thymol widely used nat-
ural phenolic as food preservative and oral care agent in
the earlier study [12] is indicative of the safety of this
compound.
Conclusions
The results presented in this study are the first informa-
tion of hydroxychavicol for antifungal activity. Hydroxy-
chavicol exhibited a broad range antifungal activity
against clinically significant human fungal species.
Further studies are therefore warranted in order to
explore of this natural compound for topical use in fun-
gal infections particularly dermatomycoses.
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